Here, Robin Foà , MD, from the University of Rome, Rome, Italy, discusses the potential of a chemotherapy-free strategy for patients…
Browsing: Acute Lymphoblastic Leukemia
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Robin Foà ,…
In this video, Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, discusses the importance of allogeneic transplant in different…
Oliver Ottmann, MD, FRCPath, of Cardiff University, Cardiff, UK, points to the need for improving the methodology of measurable residual…
In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options…
Speaking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Daniel DeAngelo, MD,…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, reflects on the differences between the treatment…
Elizabeth Macintyre, MD, PhD, of the Hôpital Necker-Enfants Malades, Paris, France, speaks about the advances made in leukemia diagnostics and…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Torsten Haferlach,…
In this interview, Torsten Haferlach, MD, of MLL Munich Leukemia Laboratory, Munich, Germany, speaks about the difficulties in diagnosing and…
Dr Jing Pan, of Beijing Boren Hospital, Beijing, P.R. China, discusses a new anti-CD22 CAR T-cell immunotherapy for pediatric relapsed/refractory…
All types of healthcare, including measurable residual disease (MRD) testing should be available to everyone throughout Europe. Speaking from the…
Measurable residual disease (MRD) testing is revolutionizing our ability to determine the disease state of a patient. In this video,…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, Elizabeth Macintyre, MD, PhD, of the…
Julia Snider, PhD, from Precision Health Economics, San Francisco, CA, talks to us about the social value of the CAR…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, in Stockholm, Sweden, Thomas Alexander, MD, PhD, of…
There is an unmet need for treatment options for acute lymphoblastic leukemia (ALL) patients who have relapsed on multiple prior…
Felice Bombaci, from the AIL patient group for chronic myeloid leukemia (CML), Rome, Italy, discusses some important key topics in…
Chemotherapy is becoming increasingly less desirable as a form of treatment, due to its systemic and burdensome nature. Instead, immunotherapy…
Therapies for acute lymphoblastic leukemia (ALL) have constantly been improving. Indeed, 35 years ago the survival rate for children was…
Measurable residual disease (MRD) is an important indicator of disease progression and prognosis. Here, Stephan Grupp, MD, PhD, of the…
While CAR T-cells are a potentially revolutionary therapy option across a variety of cancer types, their associated side effects include…
In this video, Ryan Cassaday, MD, of the University of Washington, Seattle, WA, gives an overview of recent developments in…
Tisagenlecleucel (CTL019), a CAR T-cell agent, was approved for acute lymphoblastic leukemia (ALL) treatment in children and young adults last…
Speaking from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Ryan Cassaday, MD, of the…
Neelima Denduluri, MD, discusses the significance of the improvement in the PFS fulvestrant +ribociclib arm of the MONALEESA-3 study in…
Exciting updates in the field of breast cancer were presented at the American Society of Oncology (ASCO) 2018 Annual Meeting,…
CAR T-cell monotherapies have produced promising results; however, the duration of remission needs to be optimized. Here, Jeremy Abramson, MD,…
With the recent influx of targeted, highly effective novel agents to the field of acute lymphoblastic leukemia (ALL), there is…
CAR T-cells are gaining traction as a therapy for a variety of hematological malignancies. Here, Oliver Ottmann, MD, FRCPath, of…
Mark Levis, MD, PhD, weighs in on the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who…
Acute lymphoblastic leukemia (ALL) is currently treated with a regimen of drugs that, while effective to an extent, could be…
Dr Laurie Sehn, of the BC Cancer Agency, Vancouver, BC, Canada presents: ‘Answering the unmet need in one of the…
John Leighton, MD, shares the outcomes of the Checkmate 142 study examining ipilimumab and nivolumab in metastatic colorectal cancer (mCRC)…
Atrayee Basu Mallick, MD, shares how how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual…
Tomasz M. Beer, MD, explains how immunotherapy is being integrated into CRPC treatment algorithms at Annual Meeting 2018.
Roy S. Herbst, MD, PhD, talks about drug sequencing as a result of Keynote 189 and 42 results at Annual…
Jeanny B. Aragon-Ching, MD, FACP, discusses how checkpoint inhibitors figure into the treatment algorithms for unresectable 1st line renal cell…
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, David Marks, MBBS, PhD,…
Measurable residual disease (MRD) is arguably the most useful single prognostic tool we have within the field of acute lymphoblastic…
There are promising results from a variety of studies implicating CAR T-cells in relapsed/refractory acute lymphoblastic leukemia (ALL) treatment. Here,…
Inotuzumab ozogamicin has shown extremely promising results in clinical trials for treatment of relapsed/refractory acute lymphoblastic leukemia (ALL). There are,…
We should move away from using risk factors as individual binary variables within acute lymphoblastic leukemia (ALL) research, suggests Anthony…
The Phase III INO-VATE trial (NCT01564784) showed improved rates of complete remission and overall survival in relapsed/refractory acute lymphoblastic leukemia…
Anthony Moorman, PhD, of Newcastle University, Newcastle, UK, discusses the current UKALL14 trial (NCT01085617) for adults aged 25-65 with acute…
Acute lymphoblastic leukemia (ALL) treatment regimens are long and debilitating, which is especially hard on young adults who are already…
With the remarkable success of the US Bone Marrow Transplant Clinical Trials Network (BMT CNT), founded by Mary Horowitz, in…
Measurable residual disease (MRD) is a significant prognostic factor in acute lymphoblastic leukemia (ALL), and as such it is important…
The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies…
The UK is in a leading position internationally for use of minimal residual disease (MRD) measurements in acute myeloid leukemia…
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid…
Although there have been significant advancements in the treatment of acute lymphoblastic leukemia (ALL) in the last few decade, many…
Microsatellite instability (MSI) in tumors is a known predictor of response to certain therapies in gynecological cancer. In this video,…
The field of cardio-oncology is growing on both a national and international scale. In this interview, Alex Lyon, MA, BM…
Due to the success of current treatments, patients are living longer and surviving cancer. However, certain treatments can cause cardiac…
Application of 2% Sequester Cut to Medicare Part B Drug Reimbursement is Unconstitutional and Illegal; Costing Seniors and Taxpayers Billions…
Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, highlights the importance of minimal residual disease (MRD) assessment in…
Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL;…
CAR T-cell therapy has proven effective in delivering high response rates in relapsed acute lymphoblastic leukemia (ALL) patients, but what…
Patients suffering from acute myeloid leukemia (AML) who have achieved complete remission are still at risk of relapse. Assessing blood…
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Charles Mullighan,…
Minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) is now considered to be an equal, or greater, marker…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, discusses the novel and interesting approaches…
Finding the right treatment for a specific subset of acute lymphoblastic leukemia (ALL) requires a correct diagnosis, but there are…
Charles Mullighan, MBBS (Hons), MSc, MD, from St. Jude Childrens Research Hospital, Memphis, TN, provides an overview of his talk…
Community Oncology Alliance Statement on President’s Blueprint to Lower Drug Prices Putting Cancer Patients First and Lowering Drug is Critically…
Community Oncology Alliance Names Dr. Frederick M. Schnell to Newly Created Medical Director Position Experienced Community Oncologist Will Provide Valuable…
Community Oncology Alliance Statement on White House Budget Proposal Drug Price Recommendations Administration’s Budget has Numerous Smart, Overdue Policy Solutions;…
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell dyscrasia, and can present de novo or following the…
The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben…
Systemic amyloid light-chain (AL) amyloidosis, a disease with improving outcomes using novel therapies, is increasingly recognized in the elderly, but…
New insights into the biology of multiple myeloma (MM) are continually emerging. In this interview, Martin Kaiser, MD, of the…
A large contributing factor to outcome in amyloidosis is the stage of diagnosis. Here, Giampaolo Merlini, MD, from the University…
This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on…
New insights into amyloid light-chain (AL) amyloidosis have emerged in recent years. Here, Giampaolo Merlini, MD, from the University of…
There are now many options to treated relapsed/refractory multiple myeloma (MM); however, these drugs can be costly, and access differs…
As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease.…
There are an array of new strategies evolving to manage relapsed chronic lymphocytic leukemia (CLL). In this interview, George Follows,…
The treatment of relapsed/refractory lymphoma can prove to be challenging. PEP-C (prednisone, etoposide, procarbazine, and cyclophosphamide) is an oral combination…
An exciting array of data for myeloproliferative neoplasms (MPNs) was presented at the 2018 British Society for Hematology (BSH) Annual…
An upcoming study is investigating a new therapeutic strategy for the treatment of myeloproliferative neoplasms (MPNs). In this interview, Claire…
This is an exciting time for chronic myeloid leukemia (CML) and myeloproliferative neoplasms (MPNs), with new treatments on the horizon.…
Consent for transplant, from both the patient and healthcare professionals, is critical. In this interview, Angela Leather from the Christie…
Post-transplant complications are an important issue to consider and must be managed appropriately. Here, Angela Leather from the Christie NHS…
CAR T-cell agents, as a breakthrough therapy, have their challenges. Here, Rose Ellard from Kings College Hospital NHS Foundation Trust,…
CAR T-cell therapy is a new and exciting advancement for the treatment of hematological cancers. In this interview, Rose Ellard…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and negative (<1%) tumor PD-L1 on the KEYNOTE-189…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and low (1-49%) tumor PD-L1 on the KEYNOTE-189…
Amer M Zeidan, MBBS, Gemtuzumab ozogamicin, Antibody Drug Conjugate Broad approval covering front-line & relapse settings at Imedex Great Debates…
Matthew S. Davids, MD, MMSc, Data Combining Venetoclax with Rituximab Half of patients achieved complete remission at Imedex Great Debates…
Richard R. Furman, MD, explains 17P Deleted with TP53 need to be treated differently at Imedex Great Debates 2018.
Jose F. Leis, MD, PhD, explains Chimeric Receptor Therapies for CLL Complete remission rates range from 25-50 at Imedex Great…
Richard M. Stone, MD, explains Use a PCR-based Approach for NMP1 Gene Next-gen sequencing to measure MRD at Imedex Great…
Amer M Zeidan, MBBS, CPX-351, a lysosomal formulation of 7+3 Drug has been tested with significant survival at Imedex Great…
Amer M Zeidan, MBBS, explains Midostaurin – FLT3 Inhibitor Improved survival when drug is added to standard at Imedex Great…
Matthew S. Davids, MD, MMSc, discusses Durability of Response for Agents is Short for Del17P Develop novel combination therapies
Richard R. Furman, MD, PFS has to be Emphasized for CLL Treatments Chemotherapy is unnecessary with novel combinations at Imedex…
Jose F. Leis, MD, PhD, discusses the Sequencing of Therapeutic Interventions Venetoclax outperforms chemoimmunotherapy at Imedex Great Debates 2018.
Richard M. Stone, MD, discusses 4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to…
Amer M Zeidan, MBBS, discusses Novel Treatments for Acute Myeloid Leukemia Four New Drugs Approved at Imedex Great Debates 2018.
Alison Fielding, MD, presents A Patient View at the International Kidney Cancer Symposium 2018
Lisa M Pickering, MD, presents Centralisation of RCC Management: What is the volume needed to improve? The Oncologists View: Is…
Mr. Rajesh Nair FRCS (Urol.), FEBU, MSc., presents Centralisation of Renal Cell Carcinoma Management: What is the Volume Needed to…
Guillermo de Velasco MD, PhD, presents Treatment after Immune checkpoint inhibition: Impact on biology? at the International Kidney Cancer Symposium…
Laurence Albiges, MD, PhD, presents Treatment after immune checkpoint in first/second line setting: Clinical perspective at the International Kidney Cancer…
Ravi Barod PhD FRCS (Urol) presents Minimally invasive partial nephrectomy is NOT a cause of seeding of RCC at the…
Christopher G. Wood, M.D., F.A.C.S. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center,…
Paul Russo, MD, FACS, presents DEBATE: Cancer Seeding and Minimally Invasive Kidney Tumor Surgery at the International Kidney Cancer Symposium…
Co-chair Dr. John P. Leonard summarizing the key take-home points presented during the Lymphoma session at this years Great Debates…
Co-chair Dr. David P. Steensma summarizes the key take-home points presented during the sessions on leukemia, benign hematology, and myeloid…
Guest faculty Dr. Paul G. Richardson summarizes the key take-home points from the presentations comprising this years Plasma Cell Disorders…
Dr. Jack West reviews clinical results in patients with advanced non-squamous NSCLC and high tumor PD-L1 on the KEYNOTE-189 trial,…
Sumanta Kumar Pal, M.D. Associate Professor, Department of Medical Oncology & Therapeutics Research Co-Director, Kidney Cancer Program City of Hope…
Bernard Escudier, Gustave Roussy, Villejuif, France asks teh question “Combination Trials with New IO Agents: How Can we Define the…
On Friday, November 4th, 2016, GRACE joined our partners Lineberger Comprehensive Cancer Center in Chapel Hill, NC and the Lung…
Presented by Dr. Luis E. Raez, MD, FACP, FCCP Chief of Hematology/Oncology and Medical Director of Memorial Cancer Institute (Miami,…
Brian I. Rini, MD, Cleveland Clinic discusses VEGF + I/O combinations in Renal Cell Carcinoma at the 13th European International…
Hans Hammers, MD, PhD, Associate Professor, UT Southwestern takes the pro stance during a debate on IO/IO in 1st Line…
Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses Tracking…
Dr. Lisa Derosa, MD, PhD Candidate Immunoncology – Pr. L. Zitvogel discusses The Role of the Microbiome in Immunotherapy at…
Samra Turajlic, Consultant Medical Oncologist, The Royal Marsden NHS Foundation Trust CRUK Clinician Scientist, The Francis Crick Institute discusses the…
Dr James Larkin, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust discusses “Immunotherapy: Bridging Knowledge from Melanoma” from…
Alain Ravaud MD, PhD, of Centre Hospitalier Universitaire de Bordeaux, Bordeaux CHU Bordeaux accepts the P.H.M. DeMulder Memorial Lecture with…
Tim Eisen, University of Cambridge discusses Patient Expectations of Adjuvant Therapy in Kidney Cancer at the 13th European International Kidney…
Lauren Harshman MD, Co-director of Kidney Cancer Program Dana-Farber Cancer Institute/Harvard Medical School discusses Biologic Rational For Neoadjuvant OVER Adjuvant…
Axel Bex, The Netherlands Cancer Institute Amsterdam debates the side of No Adjuvant Therapy Kidney Cancer at the 13th European…
Michael Staehler, Ludwig-Maximilians-University of Munich | LMU discusses Yes for Adjuvant Therapy with Full Dose VEGFR TKI at the 13th…
Maxine Tran, Senior lecturer and Honorary Consultant Urologist Specialist center for kidney cancer, Royal Free Hospital UCL Division of Surgery…
Tom Mitchell BMBCh, DPhil, FRCS, Academic Clinical Lecturer & Honorary Urology Registrar, Cambridge University Hospitals discusses Timing of Key Genetic…
Grant D Stewart, University Lecturer, University of Cambridge, Consultant Urological Surgeon, Addenbrookes Hospital asks the question “Screening for kidney cancer:…
The British Society for Haematology (BSH) aims to improve patient care and outcomes in the hematology field. In this interview,…
The British Society for Haematology (BSH) brings hematology professionals from all areas together at their Annual Scientifc Meeting. Speaking from…
IMPACT, the UKs first large-scale clinical trials platform for patients receiving a stem cell transplant, is launching in 2018. Here,…
Recent KEYNOTE study data has led to confusion over the significance of PD-L1 as a predictive biomarker of immunotherapy response.…
The results of KEYNOTE-024 (NCT02142738) indicated that high PD-L1 expression predicted a benefit from pembrolizumab vs. chemotherapy. However, new data…
Dr. Jack West reviews the trial design, efficacy endpoints, and toxicity results of the KEYNOTE-189 trial of pembrolizumab or placebo…
A Practice Change for ALK+ Lung Cancer Patients, Alecensa for First Line Treatment
Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field Is there a place for Lorlatinib?
Are MET Mutations Now a Mutation We Should Look for in Lung Cancer?
Dacomitinib Beats Iressa as First Line Treatment for EGFR Mutation-Positive NSCLC: New Option or Too Little Too Late?
Keytruda is Now Approved in Combination with Chemo for Advanced Non-Squamous NSCLC: What Do We Do Now?
What is PFS2 in Advanced NSCLC, and Should we Care? Unique Analysis of the KEYNOTE-024 trial     …
What is the role for Immunotherapy in Relapsed Small Cell Lung Cancer after ASCO 2017?
Emerging Options for Malignant Pleural Mesothelioma
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally…
Radiation oncologist Dr. Chris Loiselle reviews the possibility of re-treating with radiation for lung cancer, typically using stereotactic technique, in…
Why radiate a perfectly good brain? Dr. Vivek Mehta, radiation oncologist, discusses the possible role for prophylactic cranial irradiation (PCI)…
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor…
MSKCC medical oncologist Dr. Greg Riely reviews the optimal first line treatment of patients with an EGFR mutation-positive advanced lung…
Drs. Leora Horn, Ben Solomon, & Jack West consider the merits of administering immune checkpoint inhibitors concurrently with standard first…
Drs. Leora Horn, Ben Solomon, & Jack West debate whether results from a European trial of chest radiation after chemotherapy…
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib…
Dr. Nasser Hanna, Indiana University Health, describes the factors which determine whether stage III NSCLC is resectable.
Join us for the 2017 Targeted Therapies in Lung Cancer Patient Forum, Saturday, September 16, 2017, at the Taussig Cancer…
Afternoon Session – Targeted Therapies in Lung Cancer Patient Forum Breakout Webcast Recording – MET/RET/BRAF, with Dr. Karen Reckamp, Dr.…
Dr. Jame Abraham, Director of the Breast Oncology program at Taussig Cancer Institute and Co-Director of the Cleveland Clinic Lerner…
In this weeks video, Dr. Brian G.M. Durie explains which criteria and tests determine if a patients myeloma is smoldering…
Radical thoracic radiotherapy is a mainstay in the treatment of non-small cell lung cancer (NSCLC); however, the effect of cardiac…
In this weeks video, Dr. Brian G.M. Durie explains that maintenance therapy can prolong remissions and delay relapse. The BOTTOM…
In this weeks video, Dr. Brian G.M. Durie explains that if you relapse on Darzalex, it is important to carefully…
In this weeks video, Dr. Brian G.M. Durie explains why genetic sequencing tests are not yet precise enough to use…
The anti-PD-1 antibody therapy pembrolizumab is an exciting new agent for the treatment of non-small cell lung cancer (NSCLC). Here,…
The IMpower150 trial (NCT02366143) was the first to explore chemotherapy, immunotherapy with atezolizumab and anti-angiogenic therapy with bevacizumab for non-small…
Immunotherapeutic agents are increasingly becoming incorporated into clinical practice; however, there is still much to learn, including their optimal combinations,…
The Phase III KEYNOTE-024 trial (NCT02142738) compared pembrolizumab monotherapy with standard platinum-based chemotherapy for previously untreated metastatic non-small cell lung…
The European Lung Cancer Congress (ELCC) 2018, in Geneva, Switzerland, presented an array of exciting lung cancer trial updates. Speaking…
Anti-angiogenic therapy has proven to be useful tool for the treatment of non-small cell lung cancer (NSCLC) in the frontline…
The treatment of brain metastases in non-small cell lung cancer (NSCLC) is a challenge, as the majority of the drugs…
Due to constraints within the NHS treatment pathway, patients with newly diagnosed multiple myeloma (MM) who are characterized as having…
Despite the controversy surrounding the design of the Tackling EArly Morbidity and Mortality in Myeloma (TEAMM) trial (ISRCTN51731976), a Phase…
In 2016, 250 patients with relapsed and/or refractory multiple myeloma (MM) were enrolled onto the Myeloma UK (MUK) Seven trial…
An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and…
Is the addition of cyclophosphamide to pomalidomide (Pom) and dexamethasone (Dex) treatment more effective at inducing a deeper and more…
With the recent revolution of drugs for the treatment of lung cancer, particularly non-small cell lung cancer (NSCLC), what lessons…
Could being proactive, by treating lung cancer patients with next-generation drugs, help reduce the risk of acquired resistance? In this…
There are now four FDA approvals that have molecular-specific licenses for lung cancer, these include ALK rearrangements, EGFR mutations, BRAF…
How do you decide on which drug to use when treating non-small cell lung cancer (NSCLC) patients in a second-line…
Recently, due to the revolution of immunotherapy in the treatment of nonsmall cell lung cancer (NSCLC), more drugs are being…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Idasanutlin (RG7388) is an MDM2 Antagonist Induces P53-directed apoptosis at Imedex…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Awaiting Phase 3 for Luspatercept and ASTX727 Clinical…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Sotatercept is an Active Ligand Trap Relieves repression of late-stage erythropoiesis…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Caution Using Medicine Off-Label Limits learning from clinical…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses LCL161 is a SMAC mimetic Induces Apoptosis in patients with myelofibrosis…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Managing Relapse Patients Early On After Initial Therapy Clinical Trial Participation is Preferred…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Few Therapeutic MDS Options for Patients Incorporating novel…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Imetelstat, Telomerase Inhibitor Myelofibrosis Intravenous drug given every 3-4 weeks at…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Transplantation is an Option for Aggressive Lymphoma Patients w DLBL or High-Grade Lymphoma…
Marlise R. Luskin, MD, MSCE, Johns Hopkins University School of Medicine, discusses Novel & Combination therapies in MDS Results in…
John Mascarenhas, MD, Mount Sinai School of Medicine, discusses Pentraxin 2 Analogue PRM-151,Infusion agent, anti-fibrotic therapy at Imedex Great Debates…
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains 25% of Patients Relapse Early in Follicular Lymphoma New targeted agents changes approach…
In the transplant setting, nurses are a vital component of patient care. Here, Michelle Kenyon, Vice Chair of the European…
An exciting new resource is available for nurses; The European Blood and Marrow Transplantation (EBMT) Textbook for Nurses. In this…
On Saturday, September 16, 2017, patients, caregivers, family members and friends joined GRACE in Cleveland at the Taussig Cancer Center…
Advances in immunotherapy – what lung cancer patients need to know.
Dr. West discusses blaming the victim. Thanks to Steph Kang for conception, Jack West for discussion and video, Maddy Brock…
Dr. Jack West shares updates to our Lung Cancer Video Library for 2017 — Should Immunotherapy Stop in Responding Patients…
Dr. Jack West offers 2017 updates to the GRACE Lung Cancer Video Library discussion on the optimal follow-up for patients…
Dr. Nate Pennell, Director of Lung Cancer Medical Oncology at Cleveland Clinic Taussig Cancer Center shares 2017 updates for our…
We are pleased to have Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
We are pleased to have Nathan Pennell, MD, Ph.D., Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
Dr. Luis Raez, MD FACP FCCP, Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
Dr. Vamsidhar Velcheti, Hematology and Medical Oncology with the Cleveland Clinic Main Campus, joined GRACE to discuss updates to our…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
Dr. Alice Shaw, Associate Professor of Medicine at Harvard Medical School, and Attending Physician Thoracic Cancer Program at Massachusetts General…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Drs. Axel Grothey,…
Great Debates & Updates in GI Malignancies 2018 provided expert review and guidance for the evaluation and interpretation of recent…
Great Debates & Updates in GI Malignancies 2018 provided attendees with an enhanced ability to evaluate and successfully integrate optimal…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Neil Segal…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Scott Kopetz…
In this presentation from the Immunotherapy Session at the 2018 Great Debates & Updates in Gastrointestinal Malignancies, Dr. Tanios S.…
In Part 3 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
In Part 2 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
In Part 1 of the ‘Optimizing Dosing Strategy for Late-Line Therapies in mCRC’ roundtable discussion, Drs. Grothey, Bekaii-Saab, and Van…
Dr. Jack West presents early data suggesting that chemotherapy may be more effective after prior immunotherapy than otherwise.
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, explains how Drugs for Long-Term is a New Area…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Two Trials looking at Inhibitors in 1st-line Therapy…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Rucaparib is licensed as a single-agent in…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses Rucaparib, Niraparib, and Olaparib all Show Benefit. Differences…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how Patients Should Still Test for BRCA Mutations…
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, discusses how ARIEL3 Was a Phase 3 Trial Looking…
Dr. Jack West reviews new data on patterns of acquired resistance after a response to immune checkpoint inhibitors for advanced…
To improve the efficacy of immunotherapy in patients with glioblastoma (GBM), the mechanisms behind the phenomenon of why bone marrow…
Glioblastoma (GBM) is a common and aggressive cancer that starts within the brain. So far, patients with GBM who undergo…
Genetic testing is not always routinely available to breast and/or ovarian cancer patients, or those at high-risk of developing these…
Due to advancements in genetic testing, women who have breast and/or ovarian cancer, or who are at high-risk of developing…
The 2018 Annual Hematology/Oncology Pharmacy Association (HOPA) Conference, held in Denver, CO, saw many thought-provoking sessions and exciting updates. Here,…
Here, Kirollos Hanna, PharmD, BCOP, BCPS, of the University of Minnesota Medical Center, Minneapolis, MN, gives an insight into his…
Speaking from the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in Denver, CO, Kirollos Hanna, PharmD, BCOP, BCPS, of…
Following the success of a collaborative educational training event in India run by the European Blood and Marrow Transplantation Nurses…
The future is looking bright for bladder cancer, with many clinical studies of new therapeutic options underway. Speaking from the…
The European Blood and Marrow Transplantation Nurses Group (EBMT NG) started a collaborative educational training project in India, which is…
New and exciting developments on urothelial cancer were presented at the 2018 Hematology/Oncology Pharmacy Association (HOPA) Annual Conference, held in…
The European Blood and Marrow Transplantation Nurses Group (EBMT NG) ran a successful educational training event in India. Here, Meera…
Following the success of a collaborative educational training event in India run by the European Blood and Marrow Transplantation Nurses…
This activity has been designed to inform oncologists who manage patients with mCRC how to safely and effectively incorporate dose…
Dr. Jack West summarizes the evolving data shaping our understanding of the role of immune checkpoint inhibitors for patients with…
Graft versus host disease (GvHD) remains to be one of the leading causes of morbidity and mortality in patients who…
It is an exciting time in the field of graft versus host disease (GvHD) research, as new drugs for the…
At present, the standard frontline therapy of steroids for graft versus host disease (GvHD) has shown to be ineffective for…
At the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland, we asked a range of experts…
A record number of delegates attended the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland. Although…
Dr. Jack West reviews the preliminary positive result form the IMpower131 trial of chemo +/- atezolizumab immunotherapy and considers what…
Maxine Sun, MD Dana-Farber Cancer Institute, discusses how Statistical Analysis Plans are Useful for Clinician Scientists They can go over…
Walter M. Stadler, MD University of Chicago, discusses Genomic and Expression Profling Soon to be part of treatment decision making…
Maxine Sun, MD Dana-Farber Cancer Institute, discusses Planning and Identification of the Statistical Methodologies Consult biostatistician for opinions on the…